Physician profile
Joseph Harrison
NPI 1104842624
$131,080.49
in general payments reported to CMS, 2019-2025
27 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $12K · 2021: $13K · 2022: $26K · 2023: $8,975 · 2024: $8,610 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $3,949 · Travel and Lodging: $3,346 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,065.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,070.00 |
| Food and Beverage | $3,948.85 |
| Travel and Lodging | $3,346.30 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $27,374.30 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $26,365.38 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24,299.04 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $22,118.19 | 2024-2025 | Cobenfy, Opdivo |
| Sunovion Pharmaceuticals INC. | $18,593.42 | 2019-2020 | |
| Allergan, INC. | $9,322.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $456.82 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $419.57 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $399.47 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $306.21 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $257.80 | 2019-2025 | Trintellix |
| Corium, LLC | $244.21 | 2022-2025 | Azstarys |
| Lundbeck LLC | $179.14 | 2019-2025 | Rexulti |
| Abbvie INC. | $172.90 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $169.67 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $61.33 | 2023-2024 | Xelstrym, Secuado |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.44 | 2019-2021 | |
| Axsome Therapeutics, INC. | $57.32 | 2023-2025 | Auvelity |
| Biogen, INC. | $43.34 | 2024 | Zurzuvae |
| Neos Therapeutics, LP | $37.28 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $29.65 | 2023-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $28.37 | 2023 | Quviviq |
| Indivior INC. | $20.36 | 2023 | Perseris |
| Tris Pharma INC | $20.06 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $16.23 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $15.52 | 2022 | |
| Shire North American Group INC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.